Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Gut ; 71(9): 1697-1723, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35798375

RESUMO

Functional dyspepsia (FD) is a common disorder of gut-brain interaction, affecting approximately 7% of individuals in the community, with most patients managed in primary care. The last British Society of Gastroenterology (BSG) guideline for the management of dyspepsia was published in 1996. In the interim, substantial advances have been made in understanding the complex pathophysiology of FD, and there has been a considerable amount of new evidence published concerning its diagnosis and classification, with the advent of the Rome IV criteria, and management. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based diagnosis and treatment of patients. The approach to investigating the patient presenting with dyspepsia is discussed, and efficacy of drugs in FD summarised based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of pairwise and network meta-analyses. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system. These provide both the strength of the recommendations and the overall quality of evidence. Finally, in this guideline, we consider novel treatments that are in development, as well as highlighting areas of unmet need and priorities for future research.


Assuntos
Dispepsia , Dispepsia/diagnóstico , Dispepsia/terapia , Gastroenterologia , Humanos , Sociedades Médicas , Reino Unido
2.
Gut ; 70(7): 1214-1240, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33903147

RESUMO

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.


Assuntos
Terapia Cognitivo-Comportamental , Constipação Intestinal/tratamento farmacológico , Diarreia/tratamento farmacológico , Síndrome do Intestino Irritável/diagnóstico , Síndrome do Intestino Irritável/terapia , Pesquisa Biomédica , Comunicação , Constipação Intestinal/etiologia , Diarreia/etiologia , Dieta , Desenvolvimento de Medicamentos , Humanos , Hipnose , Síndrome do Intestino Irritável/complicações , Síndrome do Intestino Irritável/fisiopatologia , Educação de Pacientes como Assunto , Relações Médico-Paciente , Probióticos/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Antagonistas da Serotonina/uso terapêutico , Reino Unido
3.
Therap Adv Gastroenterol ; 11: 1756284818798791, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30302125

RESUMO

BACKGROUND: Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to improve symptoms of irritable bowel syndrome with constipation (IBS-C). Here we report data from a real-world study of linaclotide in the UK. METHODS: This 1-year, multicentre, prospective, observational study in the UK enrolled patients aged 18 years and over initiating linaclotide for IBS-C. The primary assessment was change from baseline in IBS Symptom Severity Scale (IBS-SSS) score at 12 weeks, assessed in patients with paired baseline and 12-week data. Change from baseline in IBS-SSS score at 52 weeks was a secondary assessment. Adverse events were recorded. RESULTS: In total, 202 patients were enrolled: 185 (91.6%) were female, median age was 44.9 years (range 18.1-77.2) and 84 (41.6%) reported baseline laxative use. Mean (standard deviation) baseline IBS-SSS score was 339 (92), with most patients (n = 129; 66.8%) classified as having severe disease (score ⩾300). In patients with paired data, there was a significant mean (95% confidence interval) decrease in IBS-SSS score from baseline to 12 weeks [-77.0 (-96.3, -57.7); p < 0.001; n = 124] and baseline to 52 weeks [-70.7 (-95.0, -46.5); p < 0.001; n = 76]. Overall, 174 adverse events were reported in 77 (38.1%) patients, most commonly diarrhoea (n = 54; 26.7%), abdominal pain (n = 21; 10.4%) and abdominal distension (n = 13; 6.4%). CONCLUSION: Linaclotide significantly improved IBS-SSS score at 12 and 52 weeks. These results provide insights into outcomes with linaclotide treatment over 1 year in patients with IBS-C in real-world clinical practice.

4.
Qual Life Res ; 22(7): 1761-6, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23096496

RESUMO

PURPOSE: It has been well established that how irritable bowel syndrome (IBS) patients respond to their illness experiences (physical, psychological) has a great impact on their symptoms, psychosocial functioning and quality of life. Recently it has been shown that using acceptance coping strategies (rather than control coping strategies) is linked to positive outcomes in several chronic illness contexts (e.g. chronic pain, diabetes, epilepsy).This study is intended to evaluate the factor structure and other psychometric properties of an acceptance measure adapted for the IBS population (IBSAAQ) and to investigate its possible utility in the prediction of key IBS outcomes. METHODS: A sample of 121 IBS patients attending a specialized gastroenterology clinic completed a series of self-report measures assessing acceptance of IBS, general acceptance, symptom severity, IBS impact on quality of life, general quality of life, gastrointestinal-specific anxiety, avoidant coping behaviours, depression, anxiety and stress. RESULTS: Factor analysis supported a 2-factor structure explaining 48.5% of variance. The total scale and its subscales (activity engagement/IBS willingness) were found to have adequate internal consistency (all α's > 0.80) and test-retest stability. Correlation analyses showed good convergent and concurrent validity. Regression analyses showed that the IBSAAQ and its subscales significantly contributed to the prediction of IBS outcomes. CONCLUSION: The IBSAAQ is a valid and reliable measure of acceptance in IBS. This measure might be of use for the study of the impact of coping strategies on outcomes in IBS and of the effectiveness of acceptance-based approaches (e.g. acceptance and commitment therapy).


Assuntos
Terapia de Aceitação e Compromisso , Adaptação Psicológica , Síndrome do Intestino Irritável/psicologia , Psicometria/instrumentação , Qualidade de Vida/psicologia , Inquéritos e Questionários , Adulto , Idoso , Ansiedade/diagnóstico , Ansiedade/psicologia , Depressão/diagnóstico , Depressão/psicologia , Análise Fatorial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Análise de Regressão , Índice de Gravidade de Doença , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...